GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Accumulated other comprehensive income (loss)

MAIA (MAIA Biotechnology) Accumulated other comprehensive income (loss) : $-0.02 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. MAIA Biotechnology's Accumulated other comprehensive income (loss) for the quarter that ended in Jun. 2024 was $-0.02 Mil.

MAIA Biotechnology's quarterly Accumulated other comprehensive income (loss) declined from Dec. 2023 ($-0.02 Mil) to Mar. 2024 ($-0.03 Mil) but then increased from Mar. 2024 ($-0.03 Mil) to Jun. 2024 ($-0.02 Mil).

MAIA Biotechnology's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-0.02 Mil) but then stayed the same from Dec. 2022 ($-0.02 Mil) to Dec. 2023 ($-0.02 Mil).


MAIA Biotechnology Accumulated other comprehensive income (loss) Historical Data

The historical data trend for MAIA Biotechnology's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology Accumulated other comprehensive income (loss) Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
- - -0.02 -0.02

MAIA Biotechnology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.04 -0.02 -0.03 -0.02

MAIA Biotechnology Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.


MAIA Biotechnology Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


MAIA Biotechnology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » Accumulated other comprehensive income (loss)
Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
Ramiro Guerrero director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc director, 10 percent owner, officer: Chief Executive Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire officer: Chief Financial Officer 6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Stan Smith director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie director, 10 percent owner 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Jean-manasse Theagene director 500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Steven M Chaouki director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Sergei Gryaznov officer: Chief Scientific Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea officer: Chief Medical Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606